Year-end Sale % OFF 
Abstract
The U.S. Department of Health and Human Services (DHHS) now recommends the single-tablet regimen tenofovir/FTC/elvitegravir/cobicistat (Stribild) as an alternative treatment for antiretroviral-naive HIV-infected patients with estimated creatinine clearance >70 mL/minute/1.73 m2. The new tablet was recently approved by the FDA for use in antiretroviral-naive HIV-infected patients based on the results of two …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
